Health ❯ Healthcare ❯ Chronic Diseases

Type 2 Diabetes

Management Strategies Treatment Options Cardiovascular Risk Medication Effects Weight Management Metabolic Disorders Obesity Management and Treatment GLP-1 Receptor Agonists Associated Conditions

Lilly’s Oral Drug Foundayo Matches Insulin on Heart Safety in Major Diabetes Trial

The finding sets up a near-term FDA filing under a priority review voucher.

FDA Clears Awiqli, First Once-Weekly Basal Insulin for Type 2 Diabetes

Metformin Lowers Blood Sugar Through Brain Circuit, Mouse Study Finds

FDA Approves Awiqli, First Once-Weekly Basal Insulin for Type 2 Diabetes

Wave Life Sciences Shares Plunge 30% After Early Obesity Trial Readout

Heart Risks Rebound After GLP-1 Breaks, New Data Show Continuous Use Is Safest

GLP-1 Drugs Tied to Lower Addiction Risk and Harms in Large VA Study

Abbott to Commercialize Novo Nordisk’s Semaglutide in India Under Extensior Brand

Lilly’s Oral GLP-1 Orforglipron Tops Oral Semaglutide in Lancet Phase 3 Diabetes Trial

Pfizer to Commercialize Sciwind’s GLP-1 Ecnoglutide in China Under Exclusive License

Major Lancet Analysis Finds Most Statin Label Side Effects Not Caused by the Drugs

Oral Semaglutide Cuts Serious Heart-Failure Events 22% in Type 2 Diabetes With Heart Failure

Meta-Analysis Finds GLP-1 Drugs Show Little Short-Term Impact on Obesity-Linked Cancer Risk

Real-World Study Finds Semaglutide and Tirzepatide Cut Cardiovascular Risk in Type 2 Diabetes

Metformin Blunts Exercise Benefits in Rutgers Randomized Trial

India Clears Ozempic for Type 2 Diabetes as Novo Nordisk Prepares Launch

EMA Approves Cardiovascular Indication for Novo Nordisk’s Rybelsus

17 Million U.S. Youth Eligible for GLP-1 Therapies Face Coverage and Care Barriers

Mounjaro Rivals Trulicity in Cardiovascular Safety and Lowers All-Cause Mortality

Glipizide Linked to 13% Higher Cardiovascular Risk Than DPP-4 Inhibitors